专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090264521A1 Percutaneous absorption preparation 审中-公开
标题翻译：经皮吸收制剂
公开(公告)号：US20090264521A1
公开(公告)日：2009-10-22
申请号：US12457772
申请日：2009-06-22
申请人： Yasuyuki Suzuki , Katsumi Iga , Masaomi Miyamoto
发明人： Yasuyuki Suzuki , Katsumi Iga , Masaomi Miyamoto
IPC分类号： A61K31/343
CPC分类号： A61K9/7061 , A61K9/0014 , A61K31/343 , A61K31/4355 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/18 , C07D307/93
摘要： Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night.
摘要翻译：能够通过便利的给药系统吸收具有褪黑激素受体激动剂活性的化合物的经皮吸收制剂具有有利的血药浓度 - 时间特征，并且可以对由褪黑激素分泌减少引起的疾病发挥治疗作用晚。

2. 发明授权

US5993848A Dissolution liquid for drug in iontophoresis 失效
标题翻译：药物溶出液在离子电渗疗法中的应用
公开(公告)号：US5993848A
公开(公告)日：1999-11-30
申请号：US659372
申请日：1996-06-06
申请人： Yasuyuki Suzuki , Katsumi Iga , Yukihiro Matsumoto
发明人： Yasuyuki Suzuki , Katsumi Iga , Yukihiro Matsumoto
IPC分类号： A61N1/30 , A61K31/785 , A61F13/00
CPC分类号： A61N1/30
摘要： A drug held or supported by an interface comprising a porous matrix is dissolved with a drug dissolution liquid containing a humectant, and the drug is transdermally delivered by iontophoresis. The humectant includes e.g. glycerin and other polyhydric alcohols, sugar alcohols, proline and other amino acids and acidic mucopolysaccharides. The concentration of the humectant may be about 1 to 50% by weight, and the concentration of proline or other amino acid or its salt may be about 1 to 30% by weight. The drug includes (1) a physiologically active peptide or protein with a molecular weight of 100 to 30,000 or (2) a nonpeptide physiologically active compound with a molecular weight of 100 to 1,000.
摘要翻译：由包含多孔基质的界面保持或负载的药物与含有保湿剂的药物溶解液溶解，并且通过离子电渗法透皮递送药物。保湿剂包括例如甘油等多元醇，糖醇，脯氨酸等氨基酸和酸性粘多糖。保湿剂的浓度可以为约1至50重量％，脯氨酸或其它氨基酸或其盐的浓度可以为约1至30重量％。药物包括（1）分子量为100〜30,000的生理活性肽或蛋白质，或（2）分子量为100〜1,000的非肽生理活性化合物。

3. 发明授权

US07378108B1 Percutaneous absorption preparation of compound having angiotensin II antagonistic activity 失效
标题翻译：具有血管紧张素II拮抗作用的化合物的经皮吸收制剂
公开(公告)号：US07378108B1
公开(公告)日：2008-05-27
申请号：US09913516
申请日：2000-02-18
申请人： Katsumi Iga , Yasuyuki Suzuki , Takehiko Naka
发明人： Katsumi Iga , Yasuyuki Suzuki , Takehiko Naka
IPC分类号： A61K9/70 , A61K31/535 , A61K47/00
CPC分类号： A61K9/7061 , A61K9/0014 , A61K31/4178 , A61K31/4245 , A61K47/10 , A61K47/14 , A61K47/16
摘要： The present invention provides a percutaneous absorption preparation which comprises a compound having angiotensin II antagonistic activity and which allows the compound to permeate through the skin at a desirable rate for a prolonged period.
摘要翻译：本发明提供了一种经皮吸收制剂，其包含具有血管紧张素II拮抗活性的化合物，并且允许化合物以期望的速率长时间渗透皮肤。

4. 发明授权

US06526316B2 Iontophoresis method 有权
标题翻译：离子电渗法
公开(公告)号：US06526316B2
公开(公告)日：2003-02-25
申请号：US09207605
申请日：1998-12-09
申请人： Katsumi Iga , Yasuyuki Suzuki , Masahiro Kawase
发明人： Katsumi Iga , Yasuyuki Suzuki , Masahiro Kawase
IPC分类号： A61N130
CPC分类号： A61N1/0432 , A61N1/30 , A61N1/325
摘要： A method for transdermal administration of parathyroid hormone by iontophoresis, which comprises applying electric current at least 2 times a day, which method is repeated one to four times each week, or an apparatus for the iontophoresis can be widely applied for not only the prevention or treatment of osteoporosis but also for general bone diseases which require promotion of bone morphogenesis, for example, treatment of ordinary fractures. The method of the present invention produces excellent pharmacological effects such as few side effects and a high bioavailability in long term administration for the prevention and treatment of bone diseases.
摘要翻译：通过离子电渗法透皮给药甲状旁腺激素的方法，其包括每天施加电流至少2次，该方法每周重复1-4次，或者用于离子电渗疗法的装置不仅可广泛应用于预防或治疗骨质疏松症，而且对于需要促进骨形态发生的一般骨病，例如治疗普通骨折。本发明的方法产生优异的药理作用，例如在长期给药中的副作用少，生物利用度高，用于预防并治疗骨病。

5. 发明授权

US06248349B1 Dissolution liquid for drug in iontophoresis 有权
标题翻译：药物溶出液在离子电渗疗法中的应用
公开(公告)号：US06248349B1
公开(公告)日：2001-06-19
申请号：US09137744
申请日：1998-08-21
申请人： Yasuyuki Suzuki , Katsumi Iga , Yukihiro Matsumoto
发明人： Yasuyuki Suzuki , Katsumi Iga , Yukihiro Matsumoto
IPC分类号： A61K900
CPC分类号： A61N1/30
摘要： A drug held or supported by an interface comprising a porous matrix is dissolved with a drug dissolution liquid containing a humectant, and the drug is transdermally delivered by iontophoresis. The humectant includes e.g. glycerin and other polyhydric alcohols, sugar alcohols, proline and other amino acids and acidic mucopolysaccharides. The concentration of the humectant may be about 1 to 50% by weight, and the concentration of proline or other amino acid or its salt may be about 1 to 30% by weight. The drug includes (1) a physiologically active peptide or protein with a molecular weight of 100 to 30,000 or (2) a nonpeptide physiologically active compound with a molecular weight of 100 to 1,000.
摘要翻译：由包含多孔基质的界面保持或负载的药物与含有保湿剂的药物溶解液溶解，并且通过离子电渗法透皮递送药物。保湿剂包括例如甘油等多元醇，糖醇，脯氨酸等氨基酸和酸性粘多糖。保湿剂的浓度可以为约1至50重量％，脯氨酸或其它氨基酸或其盐的浓度可以为约1至30重量％。药物包括（1）分子量为100〜30,000的生理活性肽或蛋白质，或（2）分子量为100〜1,000的非肽生理活性化合物。

6. 发明授权

US06416503B1 Matrix for iontophoreses 失效
标题翻译：离子电极矩阵
公开(公告)号：US06416503B1
公开(公告)日：2002-07-09
申请号：US08842516
申请日：1997-04-24
申请人： Yasuyuki Suzuki , Katsumi Iga , Hiroaki Okada , Yukihiro Matsumoto
发明人： Yasuyuki Suzuki , Katsumi Iga , Hiroaki Okada , Yukihiro Matsumoto
IPC分类号： A61N130
CPC分类号： A61N1/30
摘要： To provide a practical matrix for iontophoresis with markedly improved drug availability. A system for iontophoreses, which comprises an anode side matrix and a cathode side matrix, wherein the anode side matrix contains a cationized drug and the cathode side matrix contains a water soluble acidic substance. A matrix for iontophoreses comprising a drug reservoir containing a drug, the drug reservoir having a thickness of less than 0.05 mm. Iontophoresis using the iontophoretic matrix of the present invention makes it possible to administer a drug to the body at high availability.
摘要翻译：为离子电渗提供实用的基质，显着改善了药物的可用性。一种用于离子电极的系统，其包括阳极侧基质和阴极侧基质，其中阳极侧基质含有阳离子化药物，阴极侧基质含有水溶性酸性物质。一种用于离子载体的基质，其包含含有药物的药物储存器，所述药物储存器的厚度小于0.05mm。使用本发明的离子电渗基质的离子电渗疗法使得可以以高可用性将药物施用于身体。

7. 发明授权

US5252336A Liposome composition whose liposome membrane contains a polyoxyethylene derivative 失效
标题翻译：脂质体组成的脂质体膜含有聚氧乙烯衍生物
公开(公告)号：US5252336A
公开(公告)日：1993-10-12
申请号：US687918
申请日：1991-06-05
申请人： Katsumi Iga , Kazuhiro Ohkouchi , Yasuaki Ogawa
发明人： Katsumi Iga , Kazuhiro Ohkouchi , Yasuaki Ogawa
IPC分类号： A61K9/127 , B01J13/02
CPC分类号： A61K9/1272 , Y10S436/829 , Y10T428/2984
摘要： A liposome composition is obtained by using as constituent components of the liposome membrane a polyoxyethylene derivative represented by the general formula:X--O--(CH.sub.2 CH.sub.2 O).sub.n --Y (I)wherein X represents an alkanoyl group or an alkyl group, Y represents a residue of a compound having a negative charge, and n is an integer of 2 to 50, and a phospholipid. The liposome composition has good dispersibility, high drug-encapsulation property and high stability.
摘要翻译： PCT No.PCT / JP91 / 00481 Sec。 371日期1991年6月5日 102（e）1991年6月5日PCT 1991年4月12日提交PCT公布。出版物WO91 / 16040 1991年10月31日。脂质体组合物通过以脂质体膜的构成成分作为通式XO-（CH 2 CH 2 O）n Y（I）表示的聚氧乙烯衍生物，其中X表示烷酰基或烷基， Y表示具有负电荷，n为2〜50的整数的化合物的残基和磷脂。脂质体组成具有良好的分散性，高的药物包封性和高稳定性。

8. 发明授权

US5750100A Sustained releasable parenteral pharmaceutical preparations and method of producing the same 失效
标题翻译：持续可释放的肠胃外药物制剂及其制备方法
公开(公告)号：US5750100A
公开(公告)日：1998-05-12
申请号：US734636
申请日：1996-10-21
申请人： Yutaka Yamagata , Katsumi Iga , Hiroaki Okada
发明人： Yutaka Yamagata , Katsumi Iga , Hiroaki Okada
IPC分类号： A61K9/14 , A61K9/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/70 , A61K38/00 , A61K38/20 , A61K38/21 , A61K38/28 , A61K47/14 , A61K38/02
CPC分类号： A61K9/2013 , A61K38/2013 , A61K38/212 , A61K38/28 , A61K9/1617 , A61K9/70 , A61K9/0024
摘要： A parenteral pharmaceutical preparation comprises a matrix containing a physiologically active peptide or protein and a polyglycerol diester of a saturated fatty acid, and the matrix is in a solid form at room temperature. The molecular weight of the physiologically active peptide or protein is 2,000 dalton or more. The saturated fatty acid includes fatty acids having about 16 to 30 carbon atoms such as palmitic acid, stearic acid, etc. The matrix may be in a pillar or granular form. The parenteral pharmaceutical preparation can be used as an injectable solid administered subcutaneously or intramuscularly (for example, a pellet or tablet for implantation), a suppository or the like, and can release the physiologically active peptide or protein sustainedly for a prolonged period of one week or more.
摘要翻译：肠胃外药物制剂包含含有生理活性肽或蛋白质的基质和饱和脂肪酸的聚甘油二酯，并且所述基质在室温下为固体形式。生理活性肽或蛋白质的分子量为2,000道尔顿或更多。饱和脂肪酸包括具有约16至30个碳原子的脂肪酸，例如棕榈酸，硬脂酸等。基质可以是柱状或颗粒形式。肠胃外药物制剂可以用作皮下或肌肉内给药的可注射固体（例如，用于植入的丸粒或片剂），栓剂等，并且可以持续释放生理活性肽或蛋白质一周的长时间或者更多。

9. 发明授权

US5094854A Liposome composition useful for hypertheria therapy 失效
标题翻译：脂质体组合物可用于治疗高血压
公开(公告)号：US5094854A
公开(公告)日：1992-03-10
申请号：US607647
申请日：1990-10-31
申请人： Yasuaki Ogawa , Katsumi Iga , Yasutaka Igari
发明人： Yasuaki Ogawa , Katsumi Iga , Yasutaka Igari
IPC分类号： A61K9/127 , A61K9/133
CPC分类号： A61K9/1277 , A61K9/127 , A61K9/1272 , Y10S514/963 , Y10T428/2984
摘要： This invention relates to the liposome compositions which are characterized in that the phase transition temperature of the membrane is in the range of 40.degree. to 45.degree. C. and the osmotic pressure of a drug-containing solution to be entrapped in liposomes is 1.2 to 2.5 times higher than that of body fluid of warm-blooded animals. The compositions are useful for treatment of solid tumors in hyperthermia therapy.

10. 发明授权

US5837281A Stabilized interface for iontophoresis 失效
标题翻译：离子电渗疗法的稳定界面
公开(公告)号：US5837281A
公开(公告)日：1998-11-17
申请号：US614375
申请日：1996-03-12
申请人： Katsumi Iga , Masafumi Misaki , Keiichiro Okabe , Emi Kyo
发明人： Katsumi Iga , Masafumi Misaki , Keiichiro Okabe , Emi Kyo
IPC分类号： A61N1/30 , A61K9/70 , A61M37/00 , B32B3/00
CPC分类号： A61N1/30 , Y10T428/249953
摘要： An interface is formed by incorporating (1) a mixture comprising a water-soluble protein and a drug into a matrix, or preferably (2) a mixture comprising a water-soluble protein and a drug to a porous matrix coated with a cationic surfactant or other ionic surfactant. The coating amount of the ionic surfactant is about 0.1 to 50 .mu.g, and the content of the water-soluble protein is about 0.1 to 1,500 .mu.g, each per 1 cm.sup.2 of the matrix. The water-soluble protein includes an albumin and the drug includes a physiologically active peptide or protein, for example. The use of the stabilized interface inhibits decrease of the drug retaining amount, and insures an effective transdermal drug delivery with a high repeatability and accuracy.
摘要翻译：通过将（1）包含水溶性蛋白质和药物的混合物结合到基质中，或优选（2）包含水溶性蛋白质和药物的混合物到包被阳离子表面活性剂的多孔基质上形成界面，或其他离子表面活性剂。离子型表面活性剂的涂布量为0.1〜50μg左右，水溶性蛋白质的含量为0.1〜1500μg，每1cm 2的基质。水溶性蛋白质包括白蛋白，例如，药物包括生理活性肽或蛋白质。使用稳定化的界面抑制药物保留量的降低，并确保有效的透皮药物递送以高重复性和准确性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式